-

Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will participate in a panel focused on hereditary angioedema (HAE) at the 2024 Wedbush PacGrow Healthcare Conference on August 14 in New York, NY.

Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a panel titled, “HAE Ya! The Changing Face of the HAE Therapeutic Landscape” on Wednesday, August 14 at 2:30pm ET.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Contacts

Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com

Industry:

Astria Therapeutics, Inc.

NASDAQ:ATXS
Release Versions
English

Contacts

Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com

More News From Astria Therapeutics, Inc.

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. “We believe that the proposed transaction with BioCryst provides the best opportunity to advance navenibart, enabling people with HAE to potentially live free from the limitations of their disease,” said Ji...

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive results from the full enrollment group of 29 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. Conducted across 20 sites in six countries, the trial demonstrated...

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final results from the ALPHA-STAR Phase 1b/2 trial of navenibart in people living with hereditary angioedema (HAE) at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting, taking place November 6-10, 2025 in Orlando, Florida. Aleena Banerji, M.D....
Back to Newsroom